Agoracom Blog Home

Posts Tagged ‘tsx-v’

PyroGenesis $PYR to Present at Zooming with LD on April 12th $RTN $NOC $UTX $DDD.ca $HPQ.ca

Posted by AGORACOM-JC at 8:21 AM on Tuesday, April 6th, 2021
  • Mr. P. Peter Pascali, CEO and Chair of PyroGenesis, will be presenting at Zooming with LD on Monday April 12 th , 2021.

MONTREAL, April 06, 2021 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (NASDAQ: PYR) (FRA: 8PY), (the “Company”, the “Corporation” or “PyroGenesis”) a Company that designs, develops, manufactures and commercializes plasma atomized metal powder, environmentally friendly plasma waste-to-energy systems and clean plasma torch products, is pleased to announce that, Mr. P. Peter Pascali, CEO and Chair of PyroGenesis, will be presenting at Zooming with LD on Monday April 12 th , 2021.

EventZooming with LD
DateApril 12 th , 2021
PresentationApril 12 th @ 11:00AM Eastern Time
Locationhttps://us02web.zoom.us/webinar/register/WN_dhq0cziUQlexYAQD2Rnpsw

About LD Micro  

LD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visit ldmicro.com. 

In September 2020, LD Micro was acquired by SRAX, a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com. 

About PyroGenesis Canada Inc.  

PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m 2 and 2,940 m 2 manufacturing facilities, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.sec.gov. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the NASDAQ Stock Market, LLC accepts responsibility for the adequacy or accuracy of this press release.  

SOURCE PyroGenesis Canada Inc. 

For further information please contact:
Rodayna Kafal, Vice President, IR/Comms. and Strategic BD
Phone: (514) 937-0002, E-mail: [email protected]

Valeo Pharma $VPH $VPHIF Reports its First Quarter 2021 Results and Highlights $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 6:40 PM on Wednesday, March 31st, 2021
  • Valeo secured the Canadian rights to Enerzair® Breezhaler® and Atectura® Breezhaler®, two new innovative Asthma therapies
  • Q1-21 net revenues of $1.9 million , up 11 % vs Q1-20
  • Frederic Fasano appointed as President and Chief Operating Officer
  • Redesca® and Redesca HP® receive Health Canada approval, launching in Q3
  • Hesperco™ capsules at the core of a Montreal Heart Institute’s COVID-19 study

MONTREAL , March 31, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2021 .

“Our first quarter has laid the foundation for a transformational year for Valeo. The commercialization agreement with Novartis Canada positions  Valeo as one of the leading Canadian companies in respirology .  We are excited about the opportunity to enter the growing asthma market with two innovative drugs, Enerzair® Breezhaler® and Atectura® Breezhaler®.  The Canadian asthma market exceeds $700 million annually 1 and is expected to growth at 2-3% per year over the next ten years. We expect combined peak sales of these two new drugs to exceed $100 million annually.”, said Steve Saviuk , Valeo’s CEO. “With the coming launch of Redesca, our low-molecular-weight-heparin biosimilar, and the Montreal Institute of Cardiology’s ongoing Covid-19 clinical trial involving Hesperco capsules, 2021 marks a turning point in Valeo’s history”.

Commenting on the first quarter 2021 results, Luc Mainville , Senior Vice-President and Chief Financial Officer said, “Our net revenues for the quarter continued to grow and reflected the addition of several products during the latter part of our 2020 fiscal year. Our first quarter results were impacted by calendar year-end slowdown of the pharma sector as well as increase in operating expenses to support our growth initiatives. Sales & Marketing expenses increased due to the addition of Redesca’s national key account manager team. Our General & Administrative expenses also increased during the quarter as a result of the addition to the Head Office personnel and increased marketing related expenses. We expect additional investments to be made in 2021 as we prepare ourselves to support the Canadian commercialization of Enerzair® Breezhaler® and Atectura® Breezhaler® already approved by Health Canada and available for sale. We anticipate strong revenue growth in the second quarter of fiscal 2021 and accelerated growth in the coming quarters as a result of these product additions which will derive incremental margins and drive our profitability going forward.

References:

  1. IQVIA CDH June 2020

First Quarter 2021 Financial Results and Highlights

  • Net revenues were $1.9 million for the quarter ended January 31, 2021 compared to $1.7 million for the quarter ended January 31, 2020 . The increase over the previous comparable period is mainly due to the Onstryv revenue growth and the launch of new products such as Ametop, Yondelis and the launch of Sodium Ethacrynate in the U.S. ;
  • Net loss of $1.7 million for the quarter ended January 31, 2021 compared to $1.1 million for the quarter ended January 31, 2020 . The increase in net loss is a result of the increase in Sales & Marketing and General & Administrative expenses required to position Valeo for solid revenue growth in 2021; and
  • Adjusted EBITDA loss of $1.1 million for the quarter ended January 31, 2021 compared to $0.9 million for the quarter ended January 31, 2020 .

First Quarter 2021 Business and Product Highlights

  • In January 2021 , the Company received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of Redesca® and Redesca® HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ);
  • In January 2021 , the Company appointed Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer. Mr. Fasano is a seasoned Canadian and international pharma executive having lead pharmaceutical organizations in Europe and Canada. His addition augments Valeo’s senior leadership team and support expansion of Valeo’s commercial activities;
  • In December 2020 , the Company announced that its shares were eligible for electronic clearing and settlement in the U.S. through the Depository Trust Company (“DTC”);
  • In December 2020 , the Company received a Notice of Compliance from Health Canada for its Redesca and Redesca HP low molecular weight heparin (“LMWH”) biosimilars; and
  • In November 2020 , the Company received a Notice of Compliance from Health Canada granting market authorization for Amikacin and commenced shipments of Ethacrynate Sodium in the U.S. market.

Subsequent Events

  • In March 2021 , the Company entered into a Commercial and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two innovative asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate), glycopyrronium (as bromide) and mometasone furoate) and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate); and
  • In February 2021 , the Company announced that Hesperco™ capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”;

Q1 2021 Webcast and Conference Call

Valeo will host a conference call to discuss the first quarter 2021 results and highlights on Thursday April 1, 2021 at 8.30am (EST) . The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available. The numbers to access the audio replay are 1-855-859-2056 and 416-849-0833 using the following access code (5555964).

A live audio webcast of the conference call will be available via:

https://produceredition.webcasts.com/starthere.jsp?ei=1444812&tp_key=929d96e070

Financial Statements and MD&A

Valeo Pharma’s financial statements and Management’s Discussion and Analysis for the three-month ended January 31, 2021 are available on SEDAR at www.sedar.com

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Fabled Silver Gold $FCO.ca $FBSGF Reports on Drill Holes SM20-07 – 11 $RDU.ca $KTN.ca $GMBXF $EDR.ca

Posted by AGORACOM at 12:35 PM on Wednesday, March 31st, 2021
This image has an empty alt attribute; its file name is fabled-square.png

Fabled Silver Gold Corp. (“Fabled” or the “Company”) (TSXV:FCO)(OTCQB:FBSGF)(FSE:7NQ) is pleased to announce updates of diamond drill holes SM20-07 – 11 from the on-going 8,000 meter drill program on the “Santa Maria” Property in Parral, Mexico.

Peter J. Hawley, CEO and President, remarks, “We are heading into areas never explored before, with new ideas to test our structure-on-structure theory over the Property. Hole SM20-07 intercepted two broad zones of northwest trending, never seen before, semi-massive marcasite, (pyrite) in hornfels, and to the east 225 meters, we tried to cross the major C1 regional north – south fault in the center of the Property.”

Hole SM20-07 was drilled at -50 degrees and 246.0 meters in length from same drill station as hole SM20-03 at an angle of 210 degree azimuth and designed to test the tail end of two northwest trending IP anomalies labeled IPSM-08. Northwest trending anomalies or structures have not been seen previously on the Property.

Drill results clearly demonstrate the cause of the two conductive zones, with a 19.90 meter intersection from 145.50 – 165.30 meters and a second 78 meter interval from 167 – 245 meters of greenish hornfels, (a metamorphic rock formed by the contact between a mudstone / shale (clay rich rock) and a hot igneous body, usually at shallow depths), with strong chlorite / sericite alteration with 25-30% marcasite, (white iron pyrite, FeS2). See Plan View of Drill Hole Locations below.

Drill hole SM20-08 was collared approximately 225 meters east of the drill station for holes SM20-4, 5, and 6. See drill plan below as designed to drill thru the interpreted main north – south structure at an oblique angle and hit the Santa Maria structure.

The hole was drilled with NQ size core, 1 7/8th inches at -50 degrees for a premature total depth of 64.18 meters where the hole was terminated by major faulting and could not be advanced further.

Drill hole SM20-08B was a re-entry into hole SM20-08 with larger PQ size drill core, 3.36 inches in diameter, to compensate for the massive broken structure, which allowed the hole to be drilled to a final depth of 234 meters and was successful in reaching its target. Currently all sampled drill core of interest is being tested. See Cross Section View below.

Drill hole SM20-09 was drilled with PQ size core from the collar, in anticipation of bad ground conditions, at -60 degrees for a targeted depth of -250 meters to hit the Santa Maria structure, as encountered in hole 8B and was terminated prematurely at 231 meters where not only did the hole collapse due to the fault but jammed the drill rods and a section of the drill string and bit was left in the hole.

Drill hole SM20-10 was designed to follow up on the hole SM20-8B targeted intercept but also to replace the loss of hole SM20-09.

HoleSM20-10 was drilled with PQ size core from the collar, in anticipation of bad ground conditions as seen previously, at -70 degrees for a targeted depth of -220 meters to hit the Santa Maria structure, as encountered in hole SM20-08B. The hole was successful in its objective and as such stopped at a total depth of 227.5 meters. Currently all sampled drill core of interest is being tested. See Cross Section View below.

Drill hole SM20-11 is located approximately 125 meters northeast of drill hole station 4 for holes SM20-08, 8B, 9, and 10. See Plan View of Drill Stations below.

The hole was drilled due west, 270 degrees, at -60 degrees targeting the intercept of the major north – south C1 regional structure at the right angle, 90 degree. The hole was successfully completed and drilled to a total depth of 258 meters.

New roads and drill pads have been completed and the drill is currently being moved to drill station 6 for hole SM20-12. See Plan View of Drill Stations below.

Peter Hawley continues, “We are systematically taking what was previously thought of as simple E-W high grade structure and re-evaluating, with numerous successes to date, in order to develop our new concept which is seen below in the “Plan View of Drill Station Locations over IP Anomalies”. Over the next few drill holes to test blue sky potential in the north of the Property should add to the new data base as we start to dial in the focus of the remaining drill program. With the Company well funded we will continue to explore all targets as they present themselves.”

Read More: https://agoracom.com/ir/FabledSilverGold/forums/discussion/topics/758317-fabled-reports-on-drill-holes-sm20-07-11/messages/2310474#message

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Provides BioCloud Manufacturing Capacity Update $LXG

Posted by AGORACOM-JC at 8:51 AM on Wednesday, March 31st, 2021
  • Received up to $2 Million in funding from the Ontario Together Fund to accelerate commercial production of the BioCloud units.
  • To date $1.2 Million has been received from the Ontario Together Fund. In order to receive the final balance of $800,000 certain conditions are required to be met, which includes the increase of manufacturing capacity to 20,000 units per month.
  • Confirming that it has met the conditions precedent for the final $800,000 in funding

TORONTO , March 31, 2021 – Kontrol Technologies Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) (” Kontrol Technologies ” or ” Kontrol ” or ” Company “) is pleased to provide an update on its manufacturing capacity as it relates to various milestones for the Ontario Together Fund.

As a follow up to the press release dated February 4 th , 2021, CEM Specialties Inc. (” CEMSI “), a wholly owned subsidiary of Kontrol Technologies, received up to $2 Million in funding from the Ontario Together Fund to accelerate commercial production of the BioCloud units. To date $1.2 Million has been received from the Ontario Together Fund. In order to receive the final balance of $800,000 certain conditions are required to be met,  which includes the increase of manufacturing capacity to 20,000 units per month.

The Company will deliver a final package to the Ontario Together Fund in the next week, confirming that it has met the conditions precedent for the final $800,000 in funding, including the required manufacturing capacity. Manufacturing capacity is the ability to manufacture a certain number of units per month and is not a sales forecast. The final $800,000 funding balance is issued at the discretion of the Ontario Together Fund following the Company’s submission.

“As we initiated commercial production, we have made continuous improvements to the manufacturing of BioCloud,” says Paul Ghezzi , CEO of Kontrol. “Some of these improvements relate to a reduction in sizing of internal systems, reduction of electronic boards and overall streamlining of installation. This is part of the normal process of moving from individual prototypes to commercial production. We have done so in a short period of time with great effort from the entire team.”

“We have made great progress with BioCloud manufacturing,” says Jeff Stewart , CEO of OES Inc. “Through our internal capacity and the addition of manufacturing capacity with our Ontario based strategic manufacturing partners we are pleased to be able to deliver up to 20,000 units per month in manufacturing capacity.”

Global Supply Chain

Currently the global supply chain for the majority of components used in the manufacturing of BioCloud appears to be stabilizing. However, lead times on electronic components and semi-conductors, which are subject to competition from the automotive and mobile industry, have been a challenge. The Company reviews the global supply chain with its manufacturing partner OES Inc. on a routine basis. The Company has no control over potential delays and lead times in the global supply chain.

“I am proud of our team which has worked tirelessly to design and develop a technology with the primary goal of assisting in the reduction of transmittance of the SARS-CoV-2 virus and its variants through earlier detection,” says Gary Saunders , President of Kontrol BioCloud. “In addition to vaccines, technologies which can provide early alerting systems are important to help us create safer spaces and get back to normal across the global economy.”

BioCloud Reagent and Antibodies

The BioCloud unit operates to detect SARS-CoV-2, and other viruses, bacteria and fungi from the air through the use of continuous air sampling and a biological response process. The primary component which makes up the BioCloud proprietary reagent is a specifically formulated combination of antibodies. The antibodies, which are purchased from third party manufacturers, are combined, and tested by independent labs for the reaction to and detection of the SARS-CoV-2 virus.

The Company’s patented antibody cooling chamber utilizes a Peltier element technology to ensure accurate and controlled temperatures are maintained for the entire life cycle of the antibodies. In addition, the Company deploys refrigerated packaging to ensure a specific temperature range is maintained during transportation and shipping of its reagent and antibodies.

The Company continues to review various antibodies from third party manufacturers with the goal to reduce the costs of BioCloud consumables and create a large supply pool to choose from as part of its overall supply chain management.

Read More: https://agoracom.com/ir/KontrolTechnologies/forums/discussion/topics/758295-kontrol-provides-biocloud-manufacturing-capacity-update/messages/2310425#message

VIDEO – Universal PropTech $UPI CGO Frank Delves Into The Company’s Future $UPI.ca $AAT.ca $LPS.ca $EGT.ca

Posted by AGORACOM-JC at 4:33 PM on Tuesday, March 30th, 2021

AGORACOM Small Cap 60: PK Beans $BEAN.ca On Innovation and Execution of Covid Pivot $LULU

Posted by AGORACOM-JC at 11:29 AM on Tuesday, March 30th, 2021

AGORACOM Small Cap 60: Fabled Silver Gold’s Big Picture $FCO.ca $FBSGF $RDU.ca $KTN.ca $GMBXF $EDR.ca

Posted by AGORACOM at 2:48 AM on Tuesday, March 30th, 2021
This image has an empty alt attribute; its file name is fabled-square.png

AGORACOM Small Cap 60: Ruth McCartney, Digital Diva Provides Compelling Arguments for Longevity of NFTs – Liquid Avatar $LQID – ImagineAR $IP.ca $IPNFF

Posted by AGORACOM-JC at 10:24 AM on Friday, March 26th, 2021

AGORACOM Small Cap 60: FansUnite $FANS $FUNFF On Plans To Monetize Game Changing Partnership with TGS Esports $TGS.ca $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 9:51 AM on Friday, March 26th, 2021
This image has an empty alt attribute; its file name is fans-square-300x300.jpg

Peak Fintech Group $PKK.ca $PKKFF Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program $MOS.ca $MOGO.ca CTZ.ca $TRAD.ca

Posted by AGORACOM-JC at 7:56 AM on Friday, March 26th, 2021
Peak Fintech Group (@PEAK_Fintech) | Twitter
  • Engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communications program across all key markets.
  • MZ Group will work closely with Peak management to develop and implement a comprehensive capital markets strategy designed to increase the Company’s visibility throughout the investment community ahead of Peak’s anticipated listing on the Nasdaq Stock Market and thereafter.

Montreal, Quebec–(March 26, 2021) – Peak Fintech Group Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communications program across all key markets.

MZ Group will work closely with Peak management to develop and implement a comprehensive capital markets strategy designed to increase the Company’s visibility throughout the investment community ahead of Peak’s anticipated listing on the Nasdaq Stock Market and thereafter. The campaign will highlight how Peak is leveraging the Cubeler Lending Hub platform in China to automate the commercial lending process as well as how Peak plans to deploy the Lending Hub ecosystem concept in North America by the end of 2021. Powered by an analytics and artificial intelligence platform, the Cubeler Lending Hub is a nation-wide ecosystem that brings together lenders, borrowers and other participants in the commercial lending space to conduct lending and credit transactions rapidly, efficiently and with the utmost transparency.

MZ has developed a distinguished reputation as a premier resource for institutional investors, brokers, analysts and private investors. Mark Schwalenberg, CFA, Director at MZ North America, will advise Peak in all facets of corporate and financial communications, including the coordination of roadshows and investment conferences across key cities, as well as building brand awareness with financial and social media outlets.

Ted Haberfield, Chairman & President of MZ Group North America, commented: “Peak’s innovative ecosystem provides access to all data on small businesses that would be required by any lender to qualify the business for credit, including from their accounting software and bank statements. Leveraging artificial intelligence to analyze lending criteria allows Peak to match small businesses with multiple lending institutions, and therefore, increase the likelihood of funding while also minimizing risk for lenders by providing pre-qualified leads. The Company has seen wide adoption of its platform in China, and we look forward to sharing Peak’s solid position and aggressive expansion plan with our wide network of institutional investors and family offices.”

“2021 is an important inflection point for Peak, as we focus on executing our development roadmap over the coming year and prepare for an eventual Nasdaq listing,” said Johnson Joseph, President and CEO of Peak Fintech Group. “We look forward to working with Mark and the entire team at MZ Group to communicate with and introduce the Company to a whole new audience who may not yet be familiar with Peak as we continue to build long-term value for our shareholders,” concluded Johnson.

The agreement is for a term of twelve (12) months with a review after six (6) months. As compensation for the services provided, MZ Group will receive a monthly fee of US$10,000 and options to purchase 110,000 common shares of Peak. The options will have an exercise price of $2.75 CAD and will expire five (5) years from the date of their issuance.

For more information on Peak, please visit the Company’s investor relations website at http://peakfintechgroup.com/investors/. To schedule a conference call with management, please email your request to [email protected] or call Mark Schwalenberg at 312-261-6430.

About MZ Group

MZ North America (www.mzgroup.us) is the US division of MZ Group, a global leader in investor relations and corporate communications. MZ North America was founded in 1996 and provides full scale Investor Relations to both private and public companies across all industries. Supported by our exclusive one‐stop‐shop approach, MZ works with top management to support the clients’ business strategy in six integrated product and service categories: 1) IR Consulting & Outreach – full service investor relations and roadshow services; 2) ESG iQ & Advisory – reporting technology platform and audit and reporting guidance; 3) SPAC Alpha IR+ & IPO Advisory – providing critical and timely guidance through business combinations and IPOs; 4) Financial & Social Media – lead generation and social media relations; 5) Market Intelligence – real time ownership monitoring; 6) Technology Solutions – webhosting, webcasting, conference calls, distribution services and board portals. MZ North America has a global footprint with offices located in New York, Chicago, San Diego, Aliso Viejo, Austin, Minneapolis, Taipei and São Paulo.

About Peak Fintech Group Inc.

Peak Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: www.peakfintechgroup.com.